The stakeholders of the
RHU TIPITCH Project

© CHU de LILLE

INDUSTRIAL PARTNER

Overview of our scientific and technical assets

Clinical Units

  • Neurology
  • Neuroradiology
  • Interventional neuroradiology
  • Haematology

Research Centres with strong expertise

  • Neuroscience
  • Haemostatic disorders
  • Genetic

CLINICAL RESEARCH NETWORKS

PATIENT
ASSOCIATIONS

Synergistic assets between partners to meet the objectives

  • ICH Cohorts
  • Translational teams Neurosciences/haemostasis
  • 7T MRI
  • ArchiMed platform
  • Neuroimaging database
  • ICH neuroimaging
  • Imaging platform
  • Translational interventional neuroradiology
  • PET imaging

Offical partners

CHU de lille

The CHU de Lille is a major player in medical research and innovation in France. With more than 16,000 professionals and 1,800 researchers, it plays a central role in the development and implementation of scientific advances.

A centre of excellence in clinical research

Each year, 8,000 patients take part in clinical studies at the CHU de Lille, which currently sponsors 198 interventional clinical trials. The centre holds ISO 9001 certification, ensuring exceptional quality in its research activities.

A strong commitment to neurosciences and haemostasis

Neurosciences are one of the four key research priorities of the CHU de Lille. Its expertise in cerebral haemorrhage and haemostasis is supported by a multidisciplinary team bringing together neurologists, neuroradiologists, neurosurgeons, haematologists and methodologists.

Lille University Hospital (CHU de Lille) brings together several strategic departments for TIPITCH:

  • Clinical Units and INSERM CIC 1403: Expertise in methodology, statistics, and pharmacovigilance.
  • Neuroscience Departments: Long-standing collaborations with a focus on neuroinflammation and strong expertise in international clinical trials.
  • Institute of Haematology and the MHEMO network: Expertise in haemostasis and coagulation disorders, with a key role in providing access to biological samples.
  • Biological Resource Centre: Processing and preservation of biological samples for the project’s analyses.

BALT

BALT, a French company with worldwide recognition, is a leading player in the field of interventional neuroradiology.

With its expertise and continuous innovation, BALT plays a key role in the TIPITCH project, helping to transform the management of haemorrhagic stroke.

A recognised expertise in the neurovascular field

BALT offers the widest range of medical devices for treating neurovascular conditions, including:
• Micro‑catheters, stents, embolisation devices, flow diverters, and more.

Thanks to these solutions, BALT has become a major global player in the fast‑growing neurovascular market, estimated at 2 billion dollars.

As a partner in the TIPITCH project, BALT France contributes through:

  • Its expertise in research and development
  • Cutting‑edge medical technologies for clinical trials
  • Active collaboration with institutional laboratories such as Inserm, CEA, CNRS, and several university hospitals

CHRU de Nancy

The Nancy University Hospital (CHRU de Nancy) is a leading institution in the field of innovative medical imaging. Through its Clinical Investigation Centre – Innovative Technologies (CIC‑IT), it contributes to the development, validation, and implementation of new imaging technologies that benefit patients.

Expertise in medical imaging at the heart of TIPITCH

The Nancy CIC‑IT, led by Prof. Jacques Felblinger and Gabriela Hossu, is a team of 18 experts dedicated to:

  • Designing, implementing, and analysing clinical and preclinical research protocols using medical imaging
  • Developing and validating new medical devices and imaging acquisition techniques
  • Centralising and processing imaging data through the ArchiMed platform

As a key partner of Work Package 4 (WP4), CHRU de Nancy provides:

  • Expertise in the centralisation, quality control, and processing of imaging data from different imaging systems (MRI, CT, angiography)
  • Strong experience in managing multisite imaging databases, such as the ETIS registry (NCT03776877), which includes over 9,000 imaging examinations from 3,500 patients
  • Essential support for data management within TIPITCH clinical trials

Chru de Tours

The Tours University Hospital (CHRU de Tours), renowned for its excellence in neurovascular research, plays a strategic role in the TIPITCH project as the leader of Work Package 4 (WP4). With its multidisciplinary expertise and its national and international collaborations, CHRU de Tours actively contributes to advancing knowledge on intracerebral haemorrhage (ICH).

Cutting‑edge clinical and technological expertise

CHRU de Tours brings together several key structures:

  • Neurovascular and Neuroimaging Unit: Clinical expertise in acute stroke.
  • Clinical Investigation Centre – Innovative Technology (CIC‑IT 1415): Development of innovative solutions.
  • INSERM U1253 – iBrain: Translational research in neurosciences.

Under the coordination of Profs. Grégoire Boulouis and Marco Pasi, CHRU de Tours contributes:

  • Expertise drawn from 35 trials and studies on stroke conducted over the past five years, including 16 currently ongoing.
  • A major contribution to the development of an advanced imaging database within the national ETIS registry on mechanical thrombectomy (15,000 patients included).
  • Strong experience in the operational structuring of imaging research, in close collaboration with the CIC‑IT of Nancy.

CHU de Limoges

The Limoges University Hospital (CHU de Limoges) brings unique expertise in interventional neuroradiology and preclinical research. As co‑leader of Work Package 1, it plays a key role in assessing and optimising medical devices for the treatment of complex neurovascular conditions.

Advanced scientific and technical expertise

CHU de Limoges builds on the excellence of its structures and collaborations:

  • XLIM – CNRS UMR 7252: Research in bio‑health, including innovations in endovascular devices.
  • EMIS Platform: Animal experimentation, with specific models (rabbits) used to test and refine neurovascular technologies.

Under the coordination of Prof. Aymeric Rouchaud, CHU de Limoges actively contributes to:

  • The development and preclinical evaluation of a new device designed to treat cerebral haemorrhages.
  • The optimisation of endovascular technologies, in partnership with Balt, another key contributor to TIPITCH.

CHU DE TOULOUSE

The Toulouse University Hospital (CHU de Toulouse), a major player in medical research in France, stands out for its expertise in clinical studies and brain imaging. As one of the largest specialised stroke centres in the country, it plays a key role in the TIPITCH project by providing advanced imaging technologies to better understand and treat haemorrhagic stroke.

Recognised expertise in brain imaging

CHU de Toulouse brings together a team of clinicians and researchers within the INSERM U1214 unit and the Clinical Investigation Centre (CIC 1436). These teams have:

  • Conducted numerous clinical studies on intracerebral haemorrhage and brain imaging.
  • Developed unique expertise in brain MRI and PET imaging (positron emission tomography), essential tools for characterising ICH and its underlying mechanisms.

Under the scientific and technical responsibility of Prof. Nicolas Raposo, CHU de Toulouse contributes to several key components of the TIPITCH project:

  • INFINITE study: A major step forward in understanding cerebral haemorrhage through PET imaging.
  • Work Package 4: Providing expertise in cohort studies and neuroimaging data.
  • Multicentre studies: Participation in large national and international collaborative projects, strengthening the scientific network dedicated to cerebral haemorrhage.

INSERM

Inserm is the only French public institution dedicated entirely to biomedical and health research. With nearly 14,000 experts and 350 laboratories, it covers the full scientific continuum—from fundamental research to clinical application—and leads major national programmes such as France 2030.

Three Inserm joint research units (UMR) from the Nord‑Ouest region, each with complementary expertise, are involved in TIPITCH:

  • UMR 1011: Studies haemostatic disorders and their impact on haemorrhagic stroke.
  • UMR 1172: Develops experimental models and potential treatments.
  • UMR 1283: Specialises in genetics and metabolic factors in cerebrovascular diseases.

University of Lille

The University of Lille is a major driver of scientific and technological innovation, actively contributing to medical advances that will shape the healthcare of tomorrow. It brings together:

  • 80,000 students
  • 3,800 academic researchers
  • 8,000 academic and administrative staff

Expertise dedicated to innovation

Thanks to its excellence in research and its strategic collaborations with socio‑economic partners, the University of Lille contributes through:

  • Its expertise in biomedical and clinical research
  • Its close collaborations with Lille University Hospital and academic partners
  • Its experience in negotiation and commercial development with industrial partners

As a key partner, the University of Lille mobilises its researchers, engineers, and students to drive medical innovation forward. Its cutting‑edge infrastructures and equipment enable the development of new approaches to better understand and treat cerebral haemorrhage.

Supporting stakeholders

FCRIN StrokeLink Network

StrokeLink is a specialised network dedicated to research and care related to stroke. It is accredited by F‑CRIN, the French national clinical research infrastructure. Coordinated by Lille University Hospital (CHU Lille) and Toulouse University Hospital (CHU Toulouse), the network aims to improve stroke management by integrating telehealth technologies and coordinated care models. It focuses on reducing recurrent strokes, lowering hospital readmissions, and improving patients’ functional outcomes.

Alongside the project’s other partners, StrokeLink will contribute to:

  • The implementation of the clinical studies planned within the project
  • The structuring of a multimodal haemorrhagic stroke registry, gathering clinical, biological, and imaging data as part of Work Package 4 led by CHRU de Tours
  • The dissemination of scientific advances within the medical community through the work package dedicated to communication and dissemination, as well as through educational initiatives and the development of training resources to better equip healthcare professionals

Tech4health

Tech4Health, accredited by Inserm and F‑CRIN, is a French network created in 2015. It brings together experts in preclinical and clinical evaluation in the field of health technologies. The network includes more than 100 multidisciplinary specialists and works closely with institutions and industry partners to translate innovations into clinical practice.

Alongside the project’s other partners, Tech4Health will contribute to:

  • The structuring of a multimodal haemorrhagic stroke registry, bringing together clinical, biological and imaging data within Work Package 4, led by CHRU de Tours
  • The dissemination of scientific advances to the medical community through the work package dedicated to communication and dissemination, including the development of educational initiatives and training resources to better equip healthcare professionals

Patient associations

France AVC 37

France AVC 37 is an important stakeholder involved in the TIPITCH project. As the Indre‑et‑Loire regional branch of the national France AVC Federation, France AVC 37 is dedicated to providing information, prevention, and support for people affected by stroke and their families.

The association brings its expertise and, crucially, the lived experience of patients to the TIPITCH project. Its contribution helps to improve care pathways and quality of life for people living with neurological conditions, combining direct patient support, public awareness initiatives, and close collaboration with healthcare professionals.

Representatives of patient associations meet several times a year to monitor the progress of the project and help co‑design its major directions. Their involvement is concrete and essential:

  • Reviewing patient information letters to ensure clarity and accessibility
  • Advising on the presentation of documents to improve understanding
  • Providing insights on study objectives to ensure results are genuinely useful for the people concerned
  • Offering guidance on communication materials and on the most relevant quality‑of‑life indicators

French Aphasia Federation

The French National Aphasia Federation (Fédération Nationale des Aphasiques de France – FNAF) is an important stakeholder involved in the TIPITCH project. The FNAF supports people living with aphasia—a language disorder often resulting from brain injury—by promoting social reintegration and defending their rights.

The association brings its expertise and, above all, the lived experience of patients to the TIPITCH project, helping improve care pathways and quality of life for people affected by these neurological conditions. Its contribution combines direct patient support, public awareness, and close collaboration with healthcare professionals.

Representatives of patient associations meet several times a year to monitor the progress of the project and help co‑design its major directions. Their involvement is concrete and essential:

  • Reviewing patient information letters to ensure clarity and accessibility
  • Advising on the presentation of documents to improve understanding
  • Providing insights on study objectives to ensure results are genuinely useful for the people concerned
  • Offering guidance on communication materials and on the most relevant quality‑of‑life indicators